Male sexual function and its disorders: Physiology, pathophysiology, clinical investigation, and treatment

Endocrine Reviews

Volumn 22, Issue 3, 2001, Pages 342-388

  Kandeel, F R ^a   Koussa, V K T ^a   Swerdloff, R S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; SILDENAFIL; TRAZODONE; YOHIMBINE;

AGING; CLINICAL FEATURE; DRUG INDUCED DISEASE; EJACULATION; HUMAN; MALE SEXUAL DYSFUNCTION; ORGASM; PATHOPHYSIOLOGY; PENIS ERECTION; PENIS PROSTHESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW;

EID: 0034979598     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.22.3.0430     Document Type: Review

References (467)

1. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences
2. Drug therapy: Erectile dysfunction
3. Evaluation of penile nerves
4. Penile length in the flaccid and erect states: Guidelines for penile augmentation
5. Dimensions, volume and rigidity of the penis. Fundamental elements in the study of the erection and its dysfunctions
6. Sonographic measurement of penile erectile volume
7. Determination of erectile penile volume by ultrasonography
8. Clinical study of the longitudinal deformation of the flaccid penis and of its variations with aging
9. Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum
10. Nitric oxide in the penis: Physiology and pathology
11. Nitric oxide: A physiologic messenger
12. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission
13. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
14. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic necleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
15. Sildenafil, a novel effective oral therapy for male erectile dysfunction
16. +-ATPase and human corpus cavernosum smooth muscle contractility
17. Nitric oxide relaxes rabbit corpus cavernosum smooth muscle via a potassium-conductive pathway
18. A review of erectile dysfunction: New insights and more questions
19. Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum
20. Calcitonin-gene-related peptide: A possible role in human penile erection and its therapeutic application in impotent patients
21. Pharmacologic and therapeutic applicatons of α2-adrenoceptor subtypes
22. Nitric oxide synthase and vasoactive intestinal polypeptide colocalization in neurons innervating the human penile circulation
23. The effect of vasoactive intestinal polypeptide (VIP) on rabbit cavernosal smooth muscle contractility
24. Endothelium-dependent relaxation of human corpus cavernosum by bradykinin
25. The expression of functional postsynaptic alpha2-adrenoceptors in the corpus cavernosum smooth muscle
26. Local control of penile erection. Nerves, smooth muscle, and endothelium
27. Endothelin: Localization, synthesis, activity, and receptor types in human penile corpus cavernosum
28. Ability of human corpora cavernosa muscle to generate prostaglandins and thromboxane in vitro
29. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum
30. 2+ stores in smooth muscle of human penile erectile tissue
31. Physiology of male sexual function
32. Neurophysiology of erection
33. Adrenergic receptors on smooth muscle cells isolated from human penile corpus cavernosum
34. Effect of moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue
35. Postjunctional α-1- and α-2-like adrenoceptors in human isolated deep dorsal vein of the penis
36. The human penis: An unusual penetration of NPY-immunoreactive nerves within the medial muscle coat of the deep dorsal vein
37. Neurogenic contraction and relaxation of human penile deep dorsal vein
38. Is there a role of hypoxemia in penile fibrosis: A viewpoint presented to the Society for the Study of Impotence
39. The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection
40. Sexual anatomy and physiology
41. Timing of penile color flow duplex ultrasonography using a triple drug mixture
42. Hemodynamics of erection
43. Impotence and infertility in men
44. Effects of psychotropic drugs on human erection and ejaculation
45. Testosterone, preoptic dopamine, and copulation in male rats
46. The activating effect of L-dopa treatment on sexual functions and its experimental background
47. Response threshold to L-dopa in psychiatric patients
48. Sexual behavior during L-dopa treatment for Parkinsonism
49. Prolactin-screening tumors and hypogonadism in 22 men
50. Biological actions of androgens
51. Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics
52. Serum testosterone and sexual activity and interest in men
53. Serum testosterone concentration and penile tumescence changes in men
54. Androgens, behaviour and nocturnal erection in hypogonadal men: The effects of varying the replacement dose
55. The nature of androgen action on male sexuality: A combined laboratory-self-report study on hypogonadal men
56. Androgen replacement with oral testosterone undecanoate in hypogonadal men: A double-blind controlled study
57. Effects of testosterone replacement on sexual behavior in hypogonadal men
58. Changes in erectile responsiveness during androgen replacement therapy
59. Early sexual growth and activity
60. Androgen maintenance of erectile function in the rat penis
61. Hormonal changes and sexual function in aging men
62. Modulation of nitric oxide synthase activity in the penis by electrical stimulation of the cavernosal nerve
63. Erection: Physiology and endocrinology
64. Male sexual response
65. Male multiple orgasms: A descriptive study
66. Drugs and impaired male sexual function
67. Disorders of sexual function
68. Color Doppler sonography in the evaluation of erectile dysfunction
69. Morphodynamic assessment of penile circulation in impotent patients: The role of duplex and color Doppler sonography
70. Colour flow and spectral Doppler imaging after papaverine-induced penile erection in 220 impotent men: Study of temporal patterns and the importance of repeated sampling, velocity asymmetry and vascular anomalies
71. Diagnosis of arteriogenic impotence: Efficacy of duplex sonography as a screening tool
72. Dynamic infusion cavernosometry and cavernosography (DICC) and the cavernosal artery systolic occlusion pressure gradient: A complete evaluation of the hemodynamic events of a penile erection
73. Evaluation of erectile dysfunction by dynamic infusion cavernosometry and cavernosography (DICC). Multi-institutional study
74. The role of the sleep laboratory in diagnosis and treatment of impotence
75. Nocturnal penile tumescence
76. Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction
77. Evaluating the effects of an α-2 adrenoceptor antagonist on erectile function in the human male. 2. The erectile response to erotic stimuli in men with erectile dysfunction, in relation to age and in comparison with normal volunteers
78. The effects of a new α-2 adrenoceptor antagonist on sleep and nocturnal penile tumescence in normal male volunteers and men with erectile dysfunction
79. The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects
80. The sexual side-effects of antidepressant medication: A double-blind comparison of two antidepressants in a non-psychiatric population
81. β-blocker effects on sexual function in normal males
82. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men
83. Superiority of nonpharmacologic therapy compared to propanolol and placebo in men with mild hypertension: A randomized, prospective trial
84. Sexuality and aging
85. Impotence and aging: Clinical and hormonal factors
86. The effects of aging on the secretion of the common α-subunit of the glycoprotem hormones in men
87. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male aging Study
88. Decreased serum testosterone and free triiodothyronine levels in healthy middle-aged men indicate an age effect at the pituitary level
89. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizmg hormone, and Leydig cell response to human chorionic gonadotropin
90. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone
91. The regulation of 17,20 lyase activity
92. Secondary hypogonadism in older men: Its relation to impotence
93. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study
94. Testosterone replacement therapy and sleep-related erections in hypogonadal men
95. NIH Consensus Conference: Impotence
96. Diagnosis and treatment of erectile problems: Current status
97. The epidemiology of erectile dysfunction
98. The biology of sexual function
99. The psychological evaluation and therapy of psychogenic impotence
100. Sexual dysfunction in male schizophrenic patients
101. Hyposexuality and epilepsy: A community survey of hormonal and behavioral changes in male epileptics
102. Sexual dysfunction in Parkinson's disease
103. A fatal cause of sexual inadequacy in men: Adreno-leukodystrophy
104. Clinical implications of antidepressant drug effects on sexual function
105. Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice
106. Compulsive sexual behaviors
107. Erotic obsession: Relationship to hypoactive sexual desire disorder and paraphilia
108. Prevalence of impotence in the United States
109. Healthy aging and male sexual function
110. Sexual function in the elderly
111. The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study
112. Increased incidence of depressive symptoms in men with erectile dysfunction
113. Somatic symptoms in primary affective disorder. Presence and relationship to the classification of depression
114. The conceptual relationship between panic disorder and male erectile dysfunction
115. Perfectionism, marital satisfaction, and contributing factors to sexual dysfunction in men with erectile disorder and their spouses
116. The prevalence and etiology of impotence in 101 male hypertensive outpatients
117. Inhibition of gonadotropin hormone-releasing hormone release by prolactin from GT 1 neuronal cell lines through prolactin receptors
118. Hyperprolactinemia inhibits gonadotropin-releasing hormone (GnRH) stimulation of the number of pituitary GnRH receptors
119. Oestrogen modulation of gonadotropin and prolactin release in women with anovulation and their responses to clomiphene
120. Prolactin-induced modification of testosterone metabolism in man
121. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat
122. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat
123. Cigarette smoking: An independent risk factor for impotence?
124. Cigarette smoking: An independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence
125. Cigarette smoking and other vascular risk factors in vasculogenic impotence
126. Ultrastructural changes in impotent penile tissue: A comparison of 65 patients
127. Acute vasospasm of penile arteries in response to cigarette smoking
128. Nicotine and cotinine inhibit steroidogenesis in mouse Leydig cells
129. Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat
130. Sexual dysfunction in men with alcoholic liver cirrhosis. A comparative study
131. Sexual dysfunction in uremia
132. Reversal of sexual impotence in male patients with chronic obstructive pulmonary disease and hypoxemia with long-term oxygen therapy
133. Hypertension, erectile dysfunction, and occult sleep apnea
134. Diabetes, sleep disorders, and male sexual function
135. Sexual functioning morbidity among cancer survivors. Current status and future research directions
136. The assessment of sexual function in cancer patients
137. The evaluation and treatment of erectile dysfunction following organ transplantation
138. Impotence in diabetes mellitus
139. Diagnosis and treatment of sexual dysfunction in the male diabetic
140. The syndrome of thrombotic obliteration of the aortic bifurcation
141. Vasculogenic impotence: Role of the pelvic steal test
142. Magnetic resonance imaging of vascular lesions of the scrotum and penis
143. Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction
144. Penile Raynaud's phenomenon: A possible cause of erectile failure
145. Vascular lesions associated with impotence in diabetic and nondiabetic arterial occlusive disease
146. Male sexual impotence in diabetes mellitus: Vasculogenic vs. neurogenic factors
147. Venous impotence: Pathophysiology, diagnosis and treatment
148. Vascular evaluation: Is it useful in 1992?
149. Neurologic impotence
150. Sexual function in spinal cord injury men. I. Assessing sexual capability
151. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition
152. Sexual dysfunction after spinal cord injury
153. Primary erectile dysfunction in combination with congenital malformation of the cavernous bodies
154. The immunological features of Peyronie's disease
155. Sexual dysfunction in Peyronie's disease: An analysis of 222 patients without previous local plaque therapy
156. Priapism: Physiology and treatment
157. Induced priapism and its management
158. Management of pharmacologically induced prolonged penile erection with oral terbutaline in traumatic paraplegics
159. Phimosis and treatment for erectile failure
160. Cavernosal cold abscess: A rare cause of impotence
161. Congenital abnormality of corpora cavernosa and erectile dysfunction: A case report
162. Circumcision in the United States. Prevalence, prophylactic effects, and sexual practie
163. Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum
164. Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat
165. Male sexual dysfunction. Ejaculatory problems
166. Premature ejaculation: A psychophysiological review
167. Some clinical and psychometric characteristics of primary and secondary premature ejaculators
168. Sex, health and happiness
169. Sexual dysfunction in males significance of adverse childhood experiences
170. Association of sexual problems with social, psychological, and physical problems in men and women: A cross sectional population survey
171. Painful ejaculation associated with antidepressants in four patients
172. Post-ejaculatory pain syndrome
173. Safety and effectiveness of vasectomy
174. Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: A prospective biopsy study
175. The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure
176. Stress prostatitis
177. Treatment of sexual disorders in the 1990s: An integrated approach
178. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs
179. Cocaine associated priapism
180. Acidosis impairs rabbit trabecular smooth muscle contractility
181. Sexual function and dysfunction
182. Impotence
183. Approach to sexual dysfunction in the male
184. Psychological issues in diagnosis and treatment of erectile disorders
185. Klinefelter's syndrome. Clinical and laboratory findings in 50 patients
186. Diagnostic value of the penile pulse and blood pressure: A Doppler study of impotence in diabetics
187. Penile blood pressure in the evaluation of erectile impotence
188. Evaluation of impotence in older men
189. Predictive power of penile/brachial index in diagnosing male sexual impotence
190. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older men
191. Current perspectives in the neural control of penile erection
192. Evaluation of the impotent patient
193. Neurologic evaluation of erectile dysfunction
194. The Derogatis interview for sexual functioning (DISF/DISF-SR): An introductory report
195. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction
196. Reliability and validity of the Florida Sexual History Questionnaire
197. The DSFI: A multidimensional measure of sexual functioning
198. Discrimination between psychogenic and organic erectile dysfunction
199. The serum transport of steroid hormones
200. Serum bioavailability of sex steroid hormones
201. A critical evaluation of simple methods for the estimation of free testosterone in serum
202. Male gonadal dysfunction
203. High dose androgen therapy in male pseudohermaphroditism due to 5 α-reductase deficiency and disorders of the androgen receptor
204. Age-associated testosterone decline in men: Clinical issues for psychiatry
205. Low serum testosterone and sex-hormone-binding-globulin in massively obese men
206. Age-related decline of plasma bioavailable testosterone in adult men
207. Pathogenesis of the decreased androgen levels in obese men
208. Endocrine screening for sexual dysfunction using free testosterone determinations
209. Colour Doppler and duplex ultrasound assessment of Peyronie's disease in impotent men
210. The value of magnetic resonance imaging in the diagnosis of suspected penile fracture with atypical clinical findings
211. Percutaneous core biopsy of the penis
212. Mechanisms of venous leakage: A prospective clinicopathological correlation of corporeal function and structure
213. Oxygen tension modulates transforming growth factor-1 expression and PGE production in human corpus cavernosum smooth muscle cells
214. Transforming growth factor β in tissue fibrosis
215. Single potential analysis of cavernous electrical activity in spinal cord injury patients
216. Expansion without significant rigidity during nocturnal penile tumescence testing: A potential source of misinterpretation
217. Evaluation of erectile dysfunction with continuous monitoring of penile rigidity
218. Nocturnal penile rigidity measured by the snap-gauge band
219. Nocturnal penile tumescence recording with stamps: A validity study
220. A new device for measuring penile rigidity
221. New method for continuous measurement of nocturnal penile tumescence and rigidity
222. Characterization of penile erectile states using external computer-based monitoring
223. Application of nocturnal electrobio-impedance volumetric assessment: A feasibility study in men without erectile dysfunction
224. The role of the sleep laboratory in the evaluation of male erectile dysfunction
225. Diurnal penile tumescence recording in the etiological diagnosis of erectile dysfunction
226. Penile tumescence monitoring during morning naps to assess male erectile functioning: An initial study of healthy men of varied ages
227. Comparative studies of the induction of erectile response to film and fantasy in diabetic men with and without neuropathy
228. Visually stimulated erection in castrated men
229. Visual erotic stimulation for initial screening of psychogenic erectile dysfunction: A reliable noninvasive alternative?
230. Enhanced pharmacological testing in patients with erectile dysfunction
231. Effect of multidose intracorporeal injection and audiovisual sexual stimulation in vasculogenic impotence
232. Visual stimulation facilitates penile responses to vibration in men with and without erectile disorder
233. A preliminary investigation of affective and cognitive response to erotic stimulation in men before and after sex therapy
234. Duplex Doppler ultrasonography: Noninvasive assessment of penile anatomy and function
235. Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: A new diagnostic approach
236. The post-investigation questionnaire (PIO-R): A practical instrument to assess erectile response after intracavernous injection
237. Comparison of selective internal iliac pharmaco-angiography, penile brachial index and duplex sonography with pulsed Doppler analysis for the evaluation of vasculogenic (arteriogenic) impotence
238. Radioisotopic test for impotence
239. Penile radionuclide studies in impotence: An overview (editorial)
240. Human penile hemodynamics studied by a polarographic method
241. Evaluation of vasculogenic impotence by monitoring of cavernous oxygen tension
242. Penile neuropathy in insulin-dependent diabetes mellitus
243. Peripheral nerve conduction studies and bulbocavernosus reflex in the investigation of impotence
244. Neurogenic impotence: Diagnostic value of nerve conduction studies, bulbocavernosus reflex, and heart rate variability
245. Assessment of pupillary light reflex latency and darkness adapted pupil size in control subjects and in diabetic patients with and without cardiovascular autonomic neuropathy
246. Penile sympathetic skin response in erectile dysfunction
247. Acetylcholine sweatspot test for autonomic denervation
248. Hypoactive sexual desire
249. Hypoactive sexual desire disorder: An overview
250. Couples therapy for erectile disorders: Observations, obstacles, and outcomes
251. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system
252. Clinical aspects of androgen deficiency in men
253. The behavioural effects of testosterone undecanoate in adult men with Klinefelteir's syndrome: A controlled study
254. Testosterone supplementation for hypogonadal impotence: Assessment of biochemical measures and therapeutic outcomes
255. Prostate cancer after exogenous testosterone treatment for impotence
256. Sexual side effects of antidepressants: A review
257. Role of brain monoamines in male sexual behavior
258. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: A comparison with bromocriptine
259. Pharmacologic modification of psychosexual dysfunction
260. Increased libido in three men treated with trazodone
261. Venlafaxine-induced increased libido and spontaneous erections
262. The aphrodisiac effect of fenfluramine: Two case reports of a possible side effect to the use of fenfluramine in the treatment of bulimia
263. Sexual dysfunction in partial epilepsy: A deficit in physiologic sexual arousal
264. Sexual adjustment of men who have had strokes
265. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
266. Sexual function in men with diabetes type 2: Association with glycemic control
267. Erectile dysfunction in diabetic subjects in Italy
268. Dose dependent impairment of corpus cavernosal smooth muscle relaxation by HbAzc in vitro
269. The combined use of sex therapy and intrapenile injections in the treatment of impotence
270. Erectile dysfunction: A review of diagnostic and treatment procedures
271. Practical management of sexual problems
272. Male erectile disorder: Characteristics and treatment choice of a longitudinal cohort study of men
273. Treatment of erectile dysfunction with single men
274. The treatment of sexually dysfunctional men without partners: A controlled study of three behavioural group approaches
275. Relationship conflict management patterns among sex dysfunction, sex offender, and satisfied couples
276. Relapse prevention strategies and techniques in sex therapy
277. Pelvi-perineal rehabilitation for dysfunctioning erections. A clinical and anatomo-physiologic study
278. Acupuncture and hypnotic suggestions in the treatment of non-organic male sexual dysfunction
279. Pergolide mesylate: Its effects on circulating anterior pituitary hormones in man
280. Adult-onset idiopathic hypogonadotropic hypogonadism-treatable form of male infertility
281. Hypogonadotropin hypogonadism: Gonadotropin therapy
282. Hypogonadotropic hypogonadism: GnRH therapy
283. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment
284. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury
285. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra)
286. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate
287. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction
288. Sildenafih a review of its use in erectile dysfunction
289. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction
290. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease
291. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease
292. Sildenafil (Viagra) one year later: A retrospective
293. Nitric oxide in the regulation of blood flow and arterial pressure
294. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist
295. Cardiovascular effects of sildenafil citrate and recommendations for its use
296. Overall cardiovascular profile of sildenafil citrate
297. Acute myocardial infarction associated with sildenafil
298. Induction of penile erection by intracavemosal and transurethral administration of Zaprinast and prostaglandin
299. Effects of IC351 on erectile response to visual sexual stimulation
300. Pharmacological management of erectile dysfunction
301. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients
302. Double-blind trial of yohimbine in treatment of psychogenic impotence
303. Yohimbine for erectile dysfunciton: A systematic review and meta-analysis of randomized clinical trials
304. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction
305. Effect of yohimbine hydrochloride on erectile impotence: A double-blind study
306. Effect of yohimbine-trazodone on psychogenic impotence: A randomized, double-blind, placebo-controlled study
307. Oral and topical treatment of erectile dysfunction. Present and future
308. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms
309. Treatment of vasculogenic sexual dysfunction with pentoxifylline
310. Effect of oral administration of prostaglandin E1 on erectile dysfunction
311. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: Results of a double-blind, randomized, placebo-controlled study
312. Oral treatment of erectile dysfunction: From herbal remedies to designer drugs
313. Trazodone, a double blind trial for treatment of erectile dysfunction
314. Oral trazodone is not effective therapy for erectile dysfunction: A double-blind, placebo controlled trial
315. Approaches for the development of oral drug therapies for erectile dysfunction
316. Intracavernous pharmacotherapy: Treatment for the aging erectile response
317. Pathophysiology of prolonged penile erection associated with trazodone use
318. Trazodone and priapism
319. Oral trazodone as empirical therapy for erectile dysfunction: A retrospective review
320. Apomorphine-induced penile erections in Parkinson's disease
321. The neural mechanism of apomorphine-induced erection: An experimental study by comparison with electrostimulation-induced erection in the rat model
322. Effect of apomorphine on penile tumescence in men with psychogenic impotence
323. Assessment of erectogenic properties of apomorphine and yohimbine in man
324. Recovery of erectile function by the oral administration of apomorphine
325. Effect of bromocriptine in patients with apomorphine-responsive erectile impotence: An open study
326. Erectile function and naltrexone
327. Opiate antagonists in erectile dysfunction: A possible new treatment option? Results of a pilot study with naltrexone
328. Treatment of idiopathic erectile dysfunction in men with the opiate antagonist naltrexone - A double-blind study
329. α2-Adrenergic and opiate receptor blockade. Synergistic effects on anxiety in healthy subjects
330. Association of fluoxetine and return of sexual potency in three elderly men
331. Intracavernous injection therapy for male erectile dysfunction
332. Intracavernosal self-injection therapy in men with erectile dysfunction: Satisfaction and attrition in 119 patients
333. Papaverine-induced inhibition of phosphodiesterase activity in various mammalian tissues
334. Pharmacotherapy of erectile dysfunction: A review
335. Changes in penile sensitivity following papaverine-induced erection in sexually functional and dysfunctional men
336. Caverject: A new licensed prostaglandin preparation for use in erectile dysfunction
337. Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection
338. Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction
339. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience
340. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction
341. Intracavernous injection of prostaglandin E1 plus procaine in the treatment of erectile dysfunction
342. Slow injection of prostaglandin E1 decreases associated penile pain
343. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
344. An international comparison of the reliability and responsiveness of the Duke Health Profile for measuring health-related quality of life patients treated with alprostadil for erectile dysfunction
345. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction
346. Intracavernous alprostadil alfadex-an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study
347. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction
348. Comparative tolerability and efficacy of treatments for impotence
349. Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents
350. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction
351. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction
352. Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: A dose-finding study vs. placebo
353. Design and evaluation of nitrosylated α-adrenergic receptor antagonists as potential agents for the treatment of impotence
354. Intracavernous calcitonin gene-related peptide plus prostaglandin E1: Possible alternative to penile implants in selected patients
355. Effects of intracavernosal trazodone hydrochloride: Animal and human studies
356. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence
357. Pharmacologically induced erections among geriatric men
358. Intracavernous self-injection pharmacotherapy program: Analysis of results and complications
359. Rescuing the failed papaverine/phentolamine erection: A proposed synergistic action of papaverine, phentolamine and PGE1
360. Peyronie's-like plaque after penile injection of prostaglandin E1
361. Combination intracavernous pharmacotherapy in the management of male erectile dysfunction
362. Experience with triple-drug therapy in a pharmacological erection program
363. Purulent corporeal cavernositis secondary to papaverine-induced priapism
364. Hepatotoxicity related to intracavernous pharmacotherapy with papaverine
365. Penile shaft hypopigmentation: Lichen sclerosus occurring after the initiation of alprostadil intracavernous injections for erectile dysfunction
366. Iatrogenic penile foreign body
367. Improved hemodynamic response after long-term intracavernous injection for impotence
368. Atropine role in the pharamcological erection test: Study of 228 patients
369. Physiology of erection, pathophysiology of impotence, and implications of PGE1 in the control of collagen synthesis in the corpus cavernosum
370. Exploration of the deep dorsal vein of the penis using pulsed Doppler ultrasonography. Preliminary study
371. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: A double-blind, placebo controlled crossover study
372. Prospective comparison of topical minoxidil to vacuum constriction device and intracorporeal papaverine injection in treatment of erectile dysfunction due to spinal cord injury
373. Transcutaneous nitroglycerine in the treatment of erectile dysfunction: A placebo controlled clinical trial
374. Papaverine topical gel for treatment of erectile dysfunction
375. Topical minoxidil in the treatment of male erectile dysfunction
376. Topical nitrate treatment of impotence
377. Topical vasoactive cream in the treatment of erectile failure: A prospective, randomized placebo-controlled trial
378. Topical treatment of erectile dysfunction: Randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate
379. Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction
380. Liposome encapsulated prostaglandin E1 in erectile dysfunction: Correlation between in vitro delivery through foreskin and efficacy in patients
381. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil
382. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy
383. MUSE therapy: Preliminary clinical observations
384. Erectile response to transurethral alprostadil, prazosin and alprostadilprazosin combinations
385. Six years' experience with the vacuum constriction device
386. Vacuum constriction device for management of erectile impotence
387. Treating erectile dysfunction with a vacuum tumescence device: A retrospective analysis of acceptance and satisfaction
388. Vascular interventions for impotence: Lessons learned
389. Overview of current operations for impotence
390. Impotence associated with blunt pelvic and perineal trauma: Penile revascularization as a treatment option
391. Long-term follow up and selection criteria for penile revascularization in erectile failure
392. Percutaneous penile venoablation for treatment of impotence
393. Preliminary report - Combined surgical and radiological penile vein occlusion for the management of impotence caused by venous-sinusoidal incompetence
394. Effectiveness of platinum wire microcoils for venous occlusion: A study on patients treated for venogenic impotence
395. Venous surgery in erectile dysfunction: A critical report on 116 patients
396. Long-term results of penile vein ligation for impotence from venous leakage
397. Surgical treatment of venous leakage: Medium-term follow-up
398. Penile venous ligation in 18 patients with 1 to 3 years of follow up
399. Experience with penile venous surgery
400. Investigation of vascular changes following penile vein ligation
401. Prognostic factors for the postoperative outcome of penile venous surgery for venogenic erectile dysfunction
402. Venous leak surgery: Long-term follow-up of patients undergoing excision and ligation of the deep dorsal vein of the penis
403. Patient selection criteria in the surgical treatment of veno-occlusive dysfunction
404. Objective criteria in the long-term evaluation of penile venous surgery
405. Augmentation phalloplasty
406. Congenital penile deviation and its treatment with the Nesbit-Kelami technique
407. The correction of congenital penile curvature in young men
408. Lengthening shortened penis caused by Peyronie's disease using circular venous grafting and daily stretching with a vacuum erection device
409. Phallic reinnervation via the pudendal nerve
410. An evaluation of the types of penile implants
411. Long-term results with Hydroflex and Dynaflex penile prostheses: Device survival comparison to multicomponent inflatables
412. Long-term results of penile prosthetic implants
413. Expression of messenger RNA splice variants for vascular endothelial growth factor (VEGF) in the adult rat and human penis
414. Corporal tissue reconstitution using human cavernosal cells
415. Penile reconstruction using engineered cartilage rods
416. + channels perserves erectile capacity in the face of diminished neuronal innervation following 12-16 weeks of experimental diabetes in rats
417. Immunophilins promote regeneration of nitric oxide synthase (NOS) containing penile nerves and erection recovery after cavernous nerve crush injury in rats
418. The expression of HSLO transcript is largely locally restricted following intracavernous injection
419. The role of prostaglandin E as determined by expression of functional prostaglandin E receptors in human corpus cavernosum
420. Different distribution of caveolin-1 and caveolin-3 in the human corpus cavernosum: Immunohistochemical study in comparison with nitric oxice synthase nerve and low affinity nerve growth factor receptor
421. Recombinant human super-oxide-dismutase (SOD) for the treatment of Peyronie's Disease (PD)
422. Premature ejaculation: A new approach
423. Orgasmic dysfunction
424. Treatment of sexual dysfunction
425. Group treatment of premature ejaculation
426. Treatment of premature ejaculation by bibliotherapy: An experimental study
427. The practice of multimodal therapy
428. The use of serotonergic uptake inhibitors in the treatment of premature ejaculation
429. A new treatment for premature ejaculation: The rehabilitation of the pelvic floor
430. Rapid ejaculation: A review of conceptual, etiological, and treatment issues
431. Prosexual drugs: Empirical status of the "new aphrodisiacs"
432. Pharmacologic treatment of rapid ejaculation
433. Clomipramine vs. placebo in the treatment of premature ejaculation: A pilot study
434. Effectiveness mechanism of clomipramine by neurophysiological tests in subjects with true premature ejaculation
435. Clomipramine in the treatment of premature ejaculation
436. Unusual side effects of clomipramine associated with yawning
437. Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial
438. Fluoxetine and premature ejaculation: A double-blind, crossover, placebo-controlled study
439. Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: A double-blind, randomized, dose-response study
440. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 Single-blind placebo controlled crossover studies
441. α-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy
442. Nonoperative management of benign prostatic hyperplasia
443. Treatment of retrograde ejaculation with imipramine
444. α-adrenergic drugs in retrograde ejaculation
445. The use of midodrine in the treatment of ejaculation disorders following retroperitoneal lymphadenectomy
446. Evaluation and treatment of erectile dysfunction following spinal cord injury: A review
447. Clinical approach to erectile dysfunction in spinal cord injured men. A review of clinical and experimental data
448. Arterial priapism: Diagnosis, treatment and long-term follow up
449. Intracorporeal phenylephrine in the treatment of priapism
450. Metaraminol for priapism
451. Evolving concepts in the diagnosis and treatment of arterial high flow priapism
452. Peyronie's disease: An update
453. Priapism
454. The evaluation of the impotent male
455. The social organization of sexuality. Sexual practices in the United States of Massachusetts Male Aging Study
456. Health-related quality of life in Australian men remaining disease-free after radical prostatectomy
457. Health-related quality of life in men with erectile dysfunction
458. A prospective long-term follow-up study of patients evaluated for erectile dysfunction: Outcome and associated factors
459. Impotence: Etiology and management